Polysaccharide Superparamagnetic Iron Oxide(Polysaccharide Superparamagnetic Iron Oxide)

概要

基本信息

药物类型

造影剂

别名-

靶点-

作用方式-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

2型糖尿病

原研机构

正大天晴药业集团股份有限公司

在研机构-

非在研机构

正大天晴药业集团股份有限公司

权益机构-

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

2

项与 Polysaccharide Superparamagnetic Iron Oxide 相关的临床试验

NCT06051565

/ Completed临床1/2期

Open-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection for Contrast-enhanced Cardiovascular Magnetic Resonance Imaging in Patients With Type 2 Diabetes and Chronic Kidney Disease.

This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic kidney disease.

开始日期2021-11-06

申办/合作机构

正大天晴药业集团股份有限公司

NCT06010537

/ Completed早期临床1期

A Single-center, Randomized, Open-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection in Healthy Subjects to Evaluate Magnetic Resonance Imaging in Multiple Dose Groups

This is a contrast-enhanced magnetic resonance imaging (MRI) study conducted on a single-administration of polyglucose superparamagnetic iron oxide injection. Two dose groups are set up in this study, 2.5 mg/kg and 3 mg/kg, and two subjects in each group received the test drug for safety evaluation.

开始日期2021-04-28

申办/合作机构

正大天晴药业集团股份有限公司

100 项与 Polysaccharide Superparamagnetic Iron Oxide 相关的临床结果

登录后查看更多信息

100 项与 Polysaccharide Superparamagnetic Iron Oxide 相关的转化医学

登录后查看更多信息

100 项与 Polysaccharide Superparamagnetic Iron Oxide 相关的专利（医药）

登录后查看更多信息

100 项与 Polysaccharide Superparamagnetic Iron Oxide 相关的药物交易

登录后查看更多信息